These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 3872057)

  • 1. Pharmacokinetics and metabolism of bepridil.
    Benet LZ
    Am J Cardiol; 1985 Mar; 55(7):8C-13C. PubMed ID: 3872057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical pharmacology of calcium inhibitors].
    Singlas E; Martre H; Taburet AM
    Arch Mal Coeur Vaiss; 1985 Nov; 78 Spec No():15-22. PubMed ID: 3937500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcium antagonists. Pharmacokinetic properties.
    Kates RE
    Drugs; 1983 Feb; 25(2):113-24. PubMed ID: 6339196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma protein binding of bepridil.
    Pritchard JF; McKown LA; Dvorchik BH; O'Neill PJ
    J Clin Pharmacol; 1985; 25(5):347-53. PubMed ID: 3875635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of intravenous bepridil in patients with coronary disease.
    Lesko LJ; Benotti JR; Alpert JS; Brady PM; McCue JE; Weiner BH; Ockene IS
    J Pharm Sci; 1986 Oct; 75(10):952-4. PubMed ID: 3491897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between the binding site of [3H]-d-cis-diltiazem and that of other non-dihydropyridine calcium entry blockers in cardiac sarcolemma.
    Balwierczak JL; Johnson CL; Schwartz A
    Mol Pharmacol; 1987 Feb; 31(2):175-9. PubMed ID: 2433570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacology of calcium antagonists: a critical review.
    Eichelbaum M; Echizen H
    J Cardiovasc Pharmacol; 1984; 6 Suppl 7():S963-7. PubMed ID: 6085385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The binding of the calcium channel blocker, bepridil, to calmodulin.
    Itoh H; Tanaka T; Mitani Y; Hidaka H
    Biochem Pharmacol; 1986 Jan; 35(2):217-20. PubMed ID: 3484629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Digoxin and bepridil: pharmacokinetic and pharmacodynamic interactions.
    Belz GG; Wistuba S; Matthews JH
    Clin Pharmacol Ther; 1986 Jan; 39(1):65-71. PubMed ID: 3484691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nicardipine, nitrendipine, and bepridil: new calcium antagonists for cardiovascular disorders.
    Hasegawa GR
    Clin Pharm; 1988 Feb; 7(2):97-108. PubMed ID: 3280222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris.
    Hollingshead LM; Faulds D; Fitton A
    Drugs; 1992 Nov; 44(5):835-57. PubMed ID: 1280569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics of verapamil, nifedipine and diltiazem.
    Echizen H; Eichelbaum M
    Clin Pharmacokinet; 1986; 11(6):425-49. PubMed ID: 3542336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetic profile of amlodipine.
    Abernethy DR
    Am Heart J; 1989 Nov; 118(5 Pt 2):1100-3. PubMed ID: 2530866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology of calcium antagonists.
    Schwartz A; Matlib MA; Balwierczak J; Lathrop DA
    Am J Cardiol; 1985 Mar; 55(7):3C-7C. PubMed ID: 3872055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics of verapamil.
    Hamann SR; Blouin RA; McAllister RG
    Clin Pharmacokinet; 1984; 9(1):26-41. PubMed ID: 6362951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of [3H]bepridil and [3H]verapamil uptake into rabbit aortic rings.
    Mras S; Sperelakis N
    J Cardiovasc Pharmacol; 1982; 4(5):777-83. PubMed ID: 6182409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stimulation of cardiac myofilament force, ATPase activity and troponin C Ca++ binding by bepridil.
    Solaro RJ; Bousquet P; Johnson JD
    J Pharmacol Exp Ther; 1986 Aug; 238(2):502-7. PubMed ID: 2942677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the Ca2+ coordination site regulating binding of Ca2+ channel inhibitors d-cis-diltiazem, (+/-)bepridil and (-)desmethoxyverapamil to their receptor site in skeletal muscle transverse tubule membranes.
    Galizzi JP; Fosset M; Lazdunski M
    Biochem Biophys Res Commun; 1985 Oct; 132(1):49-55. PubMed ID: 2998366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypotensive effects of a calcium antagonist, bepridil, in patients with essential hypertension.
    Aoki K; Sato K
    Jpn Heart J; 1986 Sep; 27(5):693-9. PubMed ID: 3493359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of bepridil, a new antianginal agent, on ambulatory electrocardiography in human volunteers.
    Duchêne-Marullaz P; Kantelip JP; Trolèse JF
    J Cardiovasc Pharmacol; 1983; 5(3):506-10. PubMed ID: 6191153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.